Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - Adaptimmune Ltd

September 25, 2014
Adaptimmune secures $104 million in Series A Financing
Company will use funding to advance programmes in multiple cancer indications. More

June 2, 2014
Adaptimmune enters strategic cancer immunotherapy collaboration with GlaxoSmithKline
Adaptimmune Limited, a leading biotechnology company developing TCR engineered T-cells to treat cancer, today announced that it has entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialisation of its lead clinical cancer programme. More

March 25, 2014
Adaptimmune announces award of £2.1m from the Biomedical Catalyst Fund
Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer. More

December 16, 2013
Adaptimmune Announces Interim Results from a Phase I/II Trial of Engineered T Cells Targeting Cancer
Adaptimmune today announces the release of interim results from a Phase I/II clinical trial using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells. The study Chair presented these updated results today at the annual meeting of the American Society of Hematology (ASH). More

November 29, 2013
Adaptimmune appoints Dr Jonathan Knowles as Chairman of the Board
Adaptimmune, the T cell therapy company pioneering engineered T cell receptors for the treatment of cancer and infectious disease, today announced the appointment of Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect. Dr Knowles succeeds Nicholas Cross who has been Chairman of the company since foundation and will remain on the Board as Deputy Chairman. More

July 25, 2013
Adaptimmune Announces Opening of Phase I/IIa Clinical Trial in Ovarian Cancer
Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif. More

January 17, 2013
NeoStem’s Subsidiary, Progenitor Cell Therapy, Enters Into a Cell Therapy Manufacturing Services Agr
NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC (“PCT”), together with Adaptimmune Limited and Adaptimmune LLC (collectively, “Adaptimmune”), announced today a Services Agreement under which PCT will provide services to support Adaptimmune’s NYESO-1c259-T cell therapy product being developed for multiple oncology indications. More

January 7, 2013
Adaptimmune announces Exclusive License with Life Technologies Corporation on Proprietary Manufactur
Adaptimmune announces that it has secured an exclusive commercial license from Life Technologies Corporation for its intellectual property portfolio for methods of expanding and activating T cells transduced with engineered T cell receptors (TCR). Life’s Dynabeads® CD3/CD28 CTS™ are the only GMP-grade reagents commercially available for use in clinical trials practicing these patented methods for the rapid expansion of autologous T cells in T cell therapy. More

December 11, 2012
Adaptimmune Announces Preliminary Results from an Early Phase Trial of Gene Engineered T Cells Targe
Adaptimmune today announces the release of preliminary results from an early phase clinical study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells. Lead investigators for the study presented today in three separate sessions at the annual meeting of the American Society of Hematology (ASH). More

November 17, 2012
Investigators to Present Preliminary Findings for Adaptimmune’s Gene Engineered T Cells in Myeloma
(Oxford, UK and Philadelphia, PA) 16 November, 2012. Adaptimmune announces the publication of dual abstracts in today’s issue of the Journal Blood, which report preliminary results from an early phase study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells. Lead investigators for the study will be presenting the data on December 10th at the annual meeting of the American Society of Hematology (ASH). More

September 19, 2011
Adaptimmune announces New Board Appointments as clinical programmes get underway
Adaptimmune, the T cell therapy company pioneering enhanced T cell receptor-driven T cells for the treatment of cancer and infectious disease, announces two new Board appointments with immediate effect. Dr Jonathan Knowles joins the Board as a non-executive director and Dr Helen Tayton-Martin, Adaptimmune’s Chief Operating Officer, becomes an executive director. More

June 13, 2011
Adaptimmune announces Opening of Phase I/II Clinical Trial for Metastatic Melanoma at Washington Uni
Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri. More

May 26, 2011
Adaptimmune announces Opening of Phase I/II Clinical Trial in Multiple Myeloma
(Oxford, UK) 26 May, 2011. Adaptimmune announced today that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy. More

March 7, 2011
Adaptimmune announces launch of US subsidiary and appointment of Binder-Scholl as VP of Operations
Adaptimmune expands with US subsidiary to support clinical programmes for cancer. More

October 7, 2009
World’s first engineered T cell receptor trial opens with new therapy for HIV
Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, today announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients’ cells carrying an engineered T cell receptor to treat HIV More

November 10, 2008
HIV'S disguises no match for ‘Bionic Assassins’
HIV is a master of disguise, able to rapidly change its identity and hide undetected in infected cells. But now, in a long-standing collaborative research effort partially-funded by the Wellcome Trust, scientists from Oxford-based Adaptimmune Limited, in partnership with the Universities of Cardiff and Pennsylvania, have engineered immune cells to act as 'bionic assassins' that see through HIV’s many disguises. More

Data


26,254
Tech investments
From our Online Data Service
16,957
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 19€3.0MInternet services
Oct 19€6.0MBusiness applications
Oct 18€11.0MConsumer electronics
Oct 18€5.0MBusiness applications
Oct 17€5.9MBiopharmaceuticals
Oct 16€3.7MContent management
Oct 16€7.8MSensors

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.